Soluble FLT1 Gene Therapy Alleviates Brain Arteriovenous Malformation Severity | Zendy

Wan Zhu | Zendy; Fanxia Shen | Zendy; Lei Mao | Zendy; Lei Zhan | Zendy; Shuai Kang | Zendy; Zhengda Sun | Zendy; Jeffrey Nelson | Zendy; Rui Zhang | Zendy; Dingquan Zou | Zendy; Cameron M. McDougall | Zendy; Michael T. Lawton | Zendy; Thiennu H. Vu | Zendy; Zhijian Wu | Zendy; Abraham Scaria | Zendy; Peter Colosi | Zendy; John Forsayeth | Zendy; Hua Su | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Soluble FLT1 Gene Therapy Alleviates Brain Arteriovenous Malformation Severity

Author(s) -

Wan Zhu,

Fanxia Shen,

Lei Mao,

Lei Zhan,

Shuai Kang,

Zhengda Sun,

Jeffrey Nelson,

Rui Zhang,

Dingquan Zou,

Cameron M. McDougall,

Michael T. Lawton,

Thiennu H. Vu,

Zhijian Wu,

Abraham Scaria,

Peter Colosi,

John Forsayeth,

Hua Su

Publication year - 2017

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.116.015713

Subject(s) - medicine , arteriovenous malformation , genetic enhancement , inflammation , vascular endothelial growth factor , pathology , andrology , surgery , biology , gene , vegf receptors , biochemistry

Brain arteriovenous malformation (bAVM) is an important risk factor for intracranial hemorrhage. Current therapies are associated with high morbidities. Excessive vascular endothelial growth factor has been implicated in bAVM pathophysiology. Because soluble FLT1 binds to vascular endothelial growth factor with high affinity, we tested intravenous delivery of an adeno-associated viral vector serotype-9 expressing soluble FLT1 (AAV9-sFLT1) to alleviate the bAVM phenotype.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research